For weeks the peptide story was written in the future tense, waiting on a hearing room. On July 23 the room voted.
The FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 and KPV to the 503A bulk drug substances list, the set of ingredients that licensed pharmacies are allowed to compound. Notably, the panel did this over the objection of the FDA's own scientists, whose briefing materials had recommended against adding any of the seven peptides under review.
What the vote is
It is a recommendation. The committee advises, and its votes are not binding on the FDA. The agency isn't required to follow the panel, though it often does. Nothing about the legal status of any peptide changed when the hands went up.
It is also not an approval. A place on the 503A list would mean a licensed pharmacy could compound the substance for a patient with a prescription. It is not the FDA declaring any peptide safe or effective. The agency's staff still wrote that they saw a lack of evidence for effectiveness, and we report that plainly. None of these substances has been evaluated or approved by the FDA.
What still has to happen
The panel's vote is the start of a process, not the end of one. To actually change the list, the FDA has to decide whether to open formal rulemaking, publish a proposed rule, take public comment, and only then issue a final rule. That is a months-long road with more than one point where the public weighs in. We track each step on our regulatory tracker.
Why this is a supply story
Here is the through-line Peppies keeps returning to. Whatever the FDA ultimately decides, today there is still no legal, tested pharmacy path for these peptides, and that vacuum is exactly why so many Americans are receiving vials from anonymous overseas sellers. Those products are not verified for identity, potency, or sterility, and independent testing keeps turning up mislabeled and contaminated peptides. A committee vote does not make that unregulated supply any safer. A legal, tested pathway is the thing that could.
We say this openly because we disclose our interest: Peppies is an independent, for-profit venture that would benefit only from a future legal, tested market, and we make no claim that any peptide is safe or effective. Yesterday's vote was one real step in that direction. It was not the finish line.
Get notified when the FDA opens the comment window that carries legal weight.